These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. FDG PET/CT for bone and soft-tissue biopsy. Nanni C; Gasbarrini A; Cappelli A; Sandler I; Graziani T; Guidalotti P; Golfieri R; Boriani S; Fanti S Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1333-4. PubMed ID: 25693761 [No Abstract] [Full Text] [Related]
24. Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study. Yanagawa T; Saito K; Kiyohara H; Ohno T; Nakano T; Takagishi K Radiat Oncol; 2015 Dec; 10():259. PubMed ID: 26691334 [TBL] [Abstract][Full Text] [Related]
25. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Bredella MA; Caputo GR; Steinbach LS AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489 [TBL] [Abstract][Full Text] [Related]
26. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions. Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363 [TBL] [Abstract][Full Text] [Related]
27. Functional image in soft tissue sarcomas: An update of the indications of Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457 [TBL] [Abstract][Full Text] [Related]
28. Correlating metabolic activity on 18F-FDG PET/CT with histopathologic characteristics of osseous and soft-tissue sarcomas: a retrospective review of 136 patients. Rakheja R; Makis W; Skamene S; Nahal A; Brimo F; Azoulay L; Assayag J; Turcotte R; Hickeson M AJR Am J Roentgenol; 2012 Jun; 198(6):1409-16. PubMed ID: 22623556 [TBL] [Abstract][Full Text] [Related]
29. Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis. Liu F; Zhang Q; Zhu D; Liu F; Li Z; Li J; Wang B; Zhou D; Dong J Medicine (Baltimore); 2015 Sep; 94(36):e1462. PubMed ID: 26356700 [TBL] [Abstract][Full Text] [Related]
30. Impact of PET and CT in PET/CT studies for staging and evaluating treatment response in bone and soft tissue sarcomas. Piperkova E; Mikhaeil M; Mousavi A; Libes R; Viejo-Rullan F; Lin H; Rosen G; Abdel-Dayem H Clin Nucl Med; 2009 Mar; 34(3):146-50. PubMed ID: 19352275 [TBL] [Abstract][Full Text] [Related]
31. Integrated 18F-FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. Erfanian Y; Grueneisen J; Kirchner J; Wetter A; Podleska LE; Bauer S; Poeppel T; Forsting M; Herrmann K; Umutlu L Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1823-1831. PubMed ID: 28567495 [TBL] [Abstract][Full Text] [Related]
33. FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Charest M; Hickeson M; Lisbona R; Novales-Diaz JA; Derbekyan V; Turcotte RE Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1944-51. PubMed ID: 19593561 [TBL] [Abstract][Full Text] [Related]
34. The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Fuglø HM; Jørgensen SM; Loft A; Hovgaard D; Petersen MM Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1416-24. PubMed ID: 22699526 [TBL] [Abstract][Full Text] [Related]
35. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575 [TBL] [Abstract][Full Text] [Related]
36. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring]. Schramm N; Schlemmer M; Rist C; Issels R; Reiser MF; Berger F Radiologe; 2010 Apr; 50(4):339-48. PubMed ID: 20221579 [TBL] [Abstract][Full Text] [Related]
37. Volume-Based F-18 FDG PET/CT Imaging Markers Provide Supplemental Prognostic Information to Histologic Grading in Patients With High-Grade Bone or Soft Tissue Sarcoma. Andersen KF; Fuglo HM; Rasmussen SH; Petersen MM; Loft A Medicine (Baltimore); 2015 Dec; 94(51):e2319. PubMed ID: 26705220 [TBL] [Abstract][Full Text] [Related]
38. FDG PET/CT findings in rare sarcomas. Ergül N; Aydın M Rev Esp Med Nucl Imagen Mol; 2013; 32(5):324-7. PubMed ID: 23352751 [TBL] [Abstract][Full Text] [Related]
40. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin. Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]